JP4591728B2 - Eye drops for improving eye strain - Google Patents

Description

[0001]
BACKGROUND OF THE INVENTION
The present invention relates to eye drops for the purpose of improving eye strain.
[0002]
[Prior art]
Eye drops containing neostigmine methyl sulfate and vitamin B12 are used for recovery from eye strain caused by overuse or mental tension in visual display terminal (VDT) work, reading, gaze work, observation work, etc. It has been.
[0003]
Caffeine has an arousal action and is widely used as an internal solution, and as an eye drop, it has been studied as a drug solubilizing agent, but no study has been made on improving eye strain.
[0004]
[Problems to be solved by the invention]
An object of the present invention is to provide an eye drop having a high effect of improving eye strain caused by overuse of eyes or mental tension.
[0005]
[Means for Solving the Problems]
As a result of diligent research, the present inventors have found that an eye drop containing caffeine as an active ingredient can improve eye strain, and completed the present invention. In addition, the present invention has found that an ophthalmic solution combined with caffeine and menthol or taurine is very effective in improving eye strain, and has completed the present invention.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
In this invention, the compounding quantity of caffeine is 0.01 to 1.0 weight%, Preferably it is 0.1 to 0.5 weight%, More preferably, it is 0.1 to 0.15 weight%.
[0007]
Further, an eye drop in which caffeine is combined with menthol or taurine has a very high effect on improving eye strain. The blending amount of menthol is 0.005 to 0.1% by weight, preferably 0.01 to 0.05% by weight. The amount of taurine is 0.1 to 3.0% by weight, preferably 0.2 to 1.0% by weight. The pH and osmotic pressure are preferably in a range that does not irritate eyes that are causing eye strain. The pH is 5.0 to 8.0, preferably 6.5 to 7.5. The osmotic pressure is 250 to 450 mOsm, preferably 260 to 360 mOsm.
[0008]
In the eye drop of the present invention, caffeine, caffeine and menthol or taurine are added, an inorganic salt is dissolved in sterilized purified water in an amount of osmotic pressure of 250 to 450 mOsm, and the pH is adjusted with a pH regulator such as borax. It can be prepared by adjusting to 5.0 to 8.0.
[0009]
The eye drop of the present invention includes an anti-inflammatory agent (dipotassium glycyrrhizinate, epsilon aminocaproic acid, allantoin, berberine chloride, berberine sulfate, sodium azulenesulfonate, zinc sulfate, zinc lactate, lysozyme chloride, etc.), if necessary. Vitamins (vitamin B2, vitamin B6, vitamin B12, panthenol, calcium pantothenate, sodium pantothenate, vitamin A acetate, etc.), amino acids (magnesium potassium L-aspartate, potassium L-aspartate, magnesium L-aspartate) , Sodium chondroitin sulfate), preservatives (benzalkonium chloride, chlorobutanol, etc.), buffers (citric acid, boric acid, etc.), pH regulators (borax, etc.), isotonic agents (sodium chloride, etc.), Solubilizing agent (poly Oxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monooleate, etc.) can be blended within a range that does not impair the effects of the present invention.
[0010]
【The invention's effect】
According to the present invention, it is possible to provide an eye drop having a high effect of improving eye strain caused by overuse of eyes or mental tension.
[0011]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples.
[0012]
Example 1
100 mg of caffeine, 740 mg of sodium chloride, and 80 mg of potassium chloride were dissolved in 90 ml of sterilized purified water, adjusted to pH 7.4 with borax, and then sterilized purified water was added to make the total volume to 100 ml to prepare an eye drop. As a result of measurement, the osmotic pressure of this eye drop was 286 mOsm.
[0013]
Example 2
Caffeine 100 mg, menthol 10 mg, sodium chloride 740 mg, and potassium chloride 80 mg were dissolved in 90 ml of sterilized purified water, adjusted to pH 7.4 with borax, and then sterilized purified water was added to make the total amount to 100 ml to prepare an eye drop. As a result of measurement, the osmotic pressure of this eye drop was 287 mOsm.
[0014]
Example 3
100 mg of caffeine, 1000 mg of taurine, 500 mg of sodium chloride, and 100 mg of potassium chloride were dissolved in 90 ml of sterilized purified water, pH was adjusted to 7.4 with borax, and then sterilized purified water was added to make the total volume to 100 ml to prepare eye drops. As a result of the measurement, the osmotic pressure of this eye drop was 288 mOsm.
[0015]
Example 4
Dissolve 100 mg of caffeine, 10 mg of menthol, 1000 mg of taurine, 500 mg of sodium chloride and 100 mg of potassium chloride in 90 ml of sterile purified water, adjust the pH to 7.4 with borax, add sterile purified water to make the total volume 100 ml, Prepared. As a result of the measurement, the osmotic pressure of this eye drop was 290 mOsm.
[0016]
Example 5
Dissolve 500 mg of caffeine, 10 mg of menthol, 1000 mg of taurine, 500 mg of sodium chloride and 100 mg of potassium chloride in 90 ml of sterile purified water, adjust the pH to 7.4 with borax, add sterile purified water to make the total volume 100 ml, Prepared. As a result of measurement, the osmotic pressure of this eye drop was 303 mOsm.
[0017]
Comparative Example 1
Sodium chloride (750 mg) and potassium chloride (90 mg) were dissolved in sterilized purified water (90 ml), pH was adjusted to 7.4 with borax, and sterilized purified water was added to make the total amount to 100 ml. As a result of measurement, the osmotic pressure of this eye drop was 286 mOsm.
[0018]
Test example 1
The eye drop of Example 1 of the present invention was used as a specimen, and the eye drop of Comparative Example 1 was used as a control specimen.
[0019]
Eye fatigue was induced by 10 hours of VDT work (addition work) for 10 healthy people. Next, each patient was instilled with 0.1 ml of each eye drop once immediately after the VDT work was completed, before fatigue was induced (before the VDT work), immediately after the VDT work for 1 hour, and 5 minutes after the eye drop. The focus adjusting power at 15 minutes and 30 minutes after instillation was measured by a step response method using a focus adjusting power measuring device (Accomodometer AR3-SV14 [manufactured by NIDEK)]. As a result, as shown in FIG. 1, it was found that the eye drop of the present invention had a higher focus adjustment improvement rate (recovery rate of adjustment power) than the control sample.
[0020]
Calculation formula Focus adjustment improvement rate (%) = (Focus adjustment time after VDT work-Focus adjustment time after instillation) x 100 / (Focus adjustment time after VDT work-Focus adjustment time before VDT work)
[0021]
Test example 2
The eye drop of Example 1 of the present invention was used as a specimen, and the eye drop of Comparative Example 1 was used as a control specimen.
[0022]
Eye fatigue was induced by 10 hours of VDT work (addition work) for 10 healthy volunteers. Next, each patient was instilled with 0.1 ml of ophthalmic solution once at the end of the VDT work, before inducing fatigue (before the VDT work), immediately after the VDT work for 1 hour, and 5 minutes after the instillation. The subjective symptoms of eye strain after 15 minutes and 30 minutes were self-determined with a score of 0 (not felt at all) to 10 (feels very tired). As a result, as shown in FIG. 2, it was found that the ophthalmic solution of the present invention (Example 1) had a higher subjective symptom improvement rate than the ophthalmic solution of Comparative Example 1.
[0023]
Calculated subjective symptom improvement rate (%) = (Subjective symptom score after VDT work-subjective symptom score after instillation) x 100 / (Subjective symptom score after VDT work-subjective symptom score before VDT work)
[Brief description of the drawings]
FIG. 1 shows the focus adjustment improvement rate (recovery rate of adjustment power) of eye drops prepared in Example 1 as a sample and Comparative Example 1 as a control sample. The horizontal axis represents time, and the vertical axis represents the focus adjustment improvement rate. (%).
[2] represents the symptoms improvement of eye fatigue eye drops prepared in Comparative Example 1 as in Example 1 and the control sample as a sample, the horizontal axis represents time and the vertical axis improves symptoms of eyestrain The rate (%) is shown.

Claims (5)

An eye drop for improving the focus adjustment power , containing caffeine as an active ingredient. The eye drop for improving the focus adjustment power according to claim 1, comprising 0.01 to 1.00% by weight of caffeine, having a pH of 5.0 to 8.0 and an osmotic pressure of 250 to 450 mOsm. The ophthalmic solution for improving focus adjustment power according to claim 1, wherein menthol or taurine is blended. The ophthalmic solution for improving focus adjustment power according to claim 1, comprising 0.005 to 0.10% by weight of menthol. The eye drop for improving the focus adjustment power according to claim 1, comprising 0.1 to 3.0% by weight of taurine.

Images